At a glance
- Originator Fujisawa
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 07 Jan 2004 No development reported - Preclinical for Rheumatoid arthritis in Japan (PO)
- 16 May 2001 New profile
- 16 May 2001 Preclinical development for Rheumatoid arthritis in Japan (PO)